Clinical significance of NTRK family gene expression in neuroblastomas

Pediatric Blood and Cancer

Volumn 59, Issue 2, 2012, Pages 226-232

  Light, Jennifer E ^a   Koyama, Hiroshi ^a   Minturn, Jane E ^a   Ho, Ruth ^a   Simpson, Anisha M ^a   Iyer, Radhika ^a   Mangino, Jennifer L ^a   Kolla, Venkatadri ^a   London, Wendy B ^a   Brodeur, Garrett M ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

BDNF; Expression; Neuroblastoma; NGF; P75 NGFR; Prognosis; TrkA NTRK1; TrkB NTRK2; TrkC NTRK3

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; NERVE GROWTH FACTOR; NEUROTROPHIC TYROSINE KINASE RECEPTOR; PROTEIN P75; SOMATOMEDIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CHILD; DISEASE ASSOCIATION; GENE EXPRESSION; GENETIC ANALYSIS; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; NEUROBLASTOMA; PLOIDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR;

HUMANS; INFANT; NERVE GROWTH FACTORS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROGNOSIS; RECEPTOR, NERVE GROWTH FACTOR; RECEPTOR, TRKA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84861703020     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23343     Document Type: Article

References (50)

1. Brodeur GM, Hogarty MD, Mosse YP, et al. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology, 6th edition. Philadelphia: Lippincott, Williams and Wilkins; 2011. pp. 886-922.
2. Brodeur GM. Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216.
3. Brodeur GM, Minturn JE, Ho R, et al. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res 2009; 15: 3244-3250.
4. Thiele CJ, Li Z, McKee AE. On Trk-the TrkB signal transduction pathway is an increasingly important target in cancer biology. Clin Cancer Res 2009; 15: 5962-5967.
5. Nakagawara A, Arima M, Azar CG, et al. Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992; 52: 1364-1368.
6. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-854.
7. Kogner P, Barbany G, Dominici C, et al. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. Cancer Res 1993; 53: 2044-2050.
8. Suzuki T, Bogenmann E, Shimada H, et al. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst 1993; 85: 377-384.
9. Hishiki T, Saito T, Terui K, et al. Reevaluation of trkA expression as a biological marker of neuroblastoma by high-sensitivity expression analysis-a study of 106 primary neuroblastomas treated in a single institute. J Pediatr Surg 2010; 45: 2293-2298.
10. Schramm A, Vandesompele J, Schulte JH, et al. Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. Clin Cancer Res 2007; 13: 1459-1465.
11. Shimada H, Nakagawa A, Peters J, et al. TrkA expression in peripheral neuroblastic tumors: Prognostic significance and biological relevance. Cancer 2004; 101: 1873-1881.
12. Tajiri T, Higashi M, Souzaki R, et al. Classification of neuroblastomas based on an analysis of the expression of genes related to prognosis. J Pediatr Surg 2007; 42: 2046-2049.
13. Zhang J, Zheng Y, Wang Y, et al. The studies on the correlation for gene expression of tyrosine-kinase receptors and vascular endothelial growth factor in human neuroblastomas. J Pediatr Hematol Oncol 2010; 32: 180-184.
14. Ho R, Minturn JE, Simpson AM, et al. The effect of P75 on Trk receptors in neuroblastomas. Cancer Lett 2011; 305: 76-85.
15. Miozzo M, Pierotti MA, Sozzi G, et al. Human TRK proto-oncogene maps to chromosome 1q32-q41. Oncogene 1990; 5: 1411-1414.
16. Scaruffi P, Cusano R, Dagnino M, et al. Detection of DNA polymorphisms and point mutations of high-affinity nerve growth factor receptor (TrkA) in human neuroblastoma. Int J Oncol 1999; 14: 935-938.
17. Lipska BS, Drozynska E, Scaruffi P, et al. c.1810C>T polymorphism of NTRK1 gene is associated with reduced survival in neuroblastoma patients. BMC Cancer 2009; 9: 436.
18. Nakagawara A, Brodeur GM. Role of neurotrophins and their receptors in human neuroblastomas: A primary culture study. Eur J Cancer 1997; 33: 2050-2053.
19. Yamashiro DJ, Nakagawara A, Ikegaki N, et al. Expression of TrkC in favorable human neuroblastomas. Oncogene 1996; 12: 37-41.
20. Ryden M, Sehgal R, Dominici C, et al. Expression of mRNA for the neurotrophin receptor trkC in neuroblastomas with favourable tumour stage and good prognosis. Br J Cancer 1996; 74: 773-779.
21. Nakagawara A, Azar CG, Scavarda NJ, et al. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994; 14: 759-767.
22. Matsumoto K, Wada RK, Yamashiro JM, et al. Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res 1995; 55: 1798-1806.
23. Acheson A, Conover JC, Fandl JP, et al. A BDNF autocrine loop in adult sensory neurons prevents cell death [see comments]. Nature 1995; 374: 450-453.
24. Ho R, Eggert A, Hishiki T, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002; 62: 6462-6466.
25. Jaboin J, Kim CJ, Kaplan DR, et al. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3′-kinase pathway. Cancer Res 2002; 62: 6756-6763.
26. Eggert A, Grotzer MA, Ikegaki N, et al. Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells. Cancer Res 2002; 62: 1802-1808.
27. Middlemas DS, Kihl BK, Zhou J, et al. Brain-derived neurotrophic factor promotes survival and chemoprotection of human neuroblastoma cells. J Biol Chem 1999; 274: 16451-16460.
28. Nakagawara A, Liu XG, Ikegaki N, et al. Cloning and chromosomal localization of the human TRK-B tyrosine kinase receptor gene (NTRK2). Genomics 1995; 25: 538-546.
29. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-1477.
30. Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984; 224: 1121-1124.
31. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 1991; 9: 581-591.
32. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-1116.
33. George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group study. J Clin Oncol 2005; 23: 6466-6473.
34. Look AT, Hayes FA, Nitschke R, et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984; 311: 231-235.
35. Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999; 86: 364-372.
36. Shimada H, Chatten J, Newton WA, Jr., et al. Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984; 73: 405-416.
37. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005; 353: 2243-2253.
38. Maris JM, Weiss MJ, Guo C, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: A Children's Cancer Group study. J Clin Oncol 2000; 18: 1888-1899.
39. Guo C, White PS, Weiss MJ, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999; 18: 4948-4957.
40. Wang Q, Diskin S, Rappaport E, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006; 66: 6050-6062.
41. Hoerndli FJ, Toigo M, Schild A, et al. Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. Anal Biochem 2004; 335: 30-41.
42. de Souza DR, Sanabani SS, de Souza AC, et al. Prognostic impact of MYCN, DDX1, TrkA, and TrkC gene transcripts expression in neuroblastoma. Pediatr Blood Cancer 2011; 56: 749-756.
43. Ho R, Minturn JE, Hishiki T, et al. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res 2005; 65: 9868-9875.
44. Meyers MB, Shen WP, Spengler BA, et al. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J Cell Biochem 1988; 38: 87-97.
45. Kim CJ, Matsuo T, Lee KH, et al. Up-regulation of insulin-like growth factor-II expression is a feature of TrkA but not TrkB activation in SH-SY5Y neuroblastoma cells. Am J Pathol 1999; 155: 1661-1670.
46. Kiess W, Koepf G, Christiansen H, et al. Human neuroblastoma cells use either insulin-like growth factor-I or insulin-like growth factor-II in an autocrine pathway via the IGF-I receptor: Variability of IGF, IGF binding protein (IGFBP) and IGF receptor gene expression and IGF and IGFBP secretion in human neuroblastoma cells in relation to cellular proliferation. Regul Pept 1997; 72: 19-29.
47. Tacconelli A, Farina AR, Cappabianca L, et al. TrkA alternative splicing: A regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 2004; 6: 347-360.
48. Evans AE, Kisselbach KD, Yamashiro DJ, et al. Antitumor activity of CEP-751 (KT-658) on human neuroblastoma and medulloblastoma xenografts. Clin Cancer Res 1999; 5: 3594-3602.
49. Iyer R, Evans AE, Qi X, et al. Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma. Clin Cancer Res 2010; 16: 1478-1485.
50. Zage PE, Graham TC, Zeng L, et al. The selective Trk inhibitor AZ623 inhibits brain-derived neurotrophic factor-mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Cancer 2011; 117: 1321-1391.